Generic medicines in India are under fire as CDSCO battles substandard drugs, severe staff shortages, non-reporting states, and rampant MSME violations. With 196 NSQ drugs flagged in April 2025, gaps in testing and lax penalties under the Jan Vishwas Act raise alarms. CGHS beneficiaries demand quality generics, as ineffective drugs threaten public health.